Differentiated Thyroid Cancer with a Focus on Adverse Event Management

New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation without compromising long-term outcomes.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.

An updated analysis on larotrectinib showed compelling data in TRK fusion thyroid carcinoma.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.